The PmSclplus Dot is a qualitative dot immunoassay for the determination of IgG antibodies against nuclear and cytoplasmic antigens (Jo-1, PL-7, PL-12, SRP, Mi-2, Ku, PM-Scl 100 and
Scl-70) in human serum. The PmSclplus is intended as an aid in the diagnosis of systemic autoimmune diseases in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.
Diagnostic Relevance
Progressive systemic sclerosis (PSS) or systemic scleroderma is an autoimmune disease of connective tissue characterized by slowly progressive fibrosis leading to sclerosis. Scl-70 autoantibodies are pathognomonic for PSS patients.
Polymyositis and dermatomyositis are idiopathic inflammatory muscle disorders with an unknown etiology, however, autoantibodies to t-RNA transferases like Jo-1, PL-7, and PL-12 are found in myositis patients. Antibodies to SRP are also specific markers for Polymyositis. Mi-2 autoantibodies are detected almost exclusively in patients with dermatomyositis. Patients tested positive for Mi-2 have a relatively mild clinical course.
Indication - Systemic autoimmune diseases
Description - Dot Immunoassay for the qualiative determination of IgG antibodies against nuclear and cytoplasmic antigens in human serum
Format - Test strips coated with Jo-1, PL-7, PL-12, SRP, Mi-2, Ku, PM-Scl 100 and Scl-70
Total incubation time - 80 min.
Sample volume - 10 µL serum
No. of determinations - 24 x 8